Last reviewed · How we verify
Ozempic® — clinical trials
Ozempic activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose levels in type 2 diabetes.
Key trials
- A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes · NA
- Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
- A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
- A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment
- Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists · PHASE4
- Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
- UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study · PHASE2
- Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. · PHASE1
- Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes · PHASE3
- Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus · PHASE3
- Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
- Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes · PHASE3
See also
- Full profile: Ozempic®
- Side effects: /side-effects
- Dosage & administration: /dosage
- Mechanism of action: /mechanism
- Cost & pricing: /cost
- Drug interactions: /interactions
- Patents & exclusivity: /patents
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing